Liz Coddington Appointed CFO of Peloton

Peloton Interactive, Inc. (NASDAQ: PTON) today announced it has appointed Liz Coddington as the company’s Chief Financial Officer, effective June 13, 2022.

Liz Coddington brings more than 20 years of experience in financial planning and analysis and operational finance, and has a proven track record of driving growth and building high-performance finance teams. She succeeds Jill Woodworth, who has decided to step down as Peloton’s Chief Financial Officer after serving the company since 2018.

Ms. Woodworth will serve as a consultant for Peloton on an interim basis, ensuring a smooth transition and supporting the company in preparation to report its FY2022 financial results.

Most recently, Ms. Coddington served as Vice President of Finance for Amazon Web Services. Prior to Amazon Web Services, she held senior leadership roles at B2B and consumer-facing companies, including as CFO of Adara and Walmart.com, as well as Vice President, Financial Planning and Analysis of Netflix.

She holds a Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology and a Master of Business Administration from the University of North Carolina at Chapel Hill.

Peloton CEO Barry McCarthy said, “Liz is a deeply talented finance executive and will be an invaluable addition to Peloton’s leadership team. Having worked at some of the strongest and most recognizable technology brands, she not only brings the expertise needed to run our finance organization, but she has a critical understanding of what it takes to drive growth and operational excellence. I have seen her intellect, abilities, and leadership firsthand and am excited to work closely with her as we execute the next phase of Peloton’s journey.”

Mr. McCarthy continued, “I would like to thank Jill for four years of dedicated service. She scaled the global finance function through an extraordinary period, led the company through its IPO, and has been an integral member of the leadership team. We wish Jill well in the next phase of her career and are grateful for all her contributions.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.